Stalevo is a fixed-dose combination that delivers levodopa, benserazide, and carbidopa together. It is prescribed for the symptomatic treatment of parkinson's disease by restoring missing dopamine in the brain. The levodopa component is converted into dopamine by neuronal cells after crossing the blood-brain barrier. Benserazide and carbidopa work peripherally to prevent premature conversion of levodopa into dopamine outside the central nervous system, thereby increasing the amount that reaches the brain. Once inside the brain, dopamine interacts with d2 receptors, which are involved in motor control and help smooth involuntary movements. By enhancing dopamine availability, Stalevo improves gait stability, reduces rigidity, and decreases tremor in affected individuals. Overall the medication targets the neurodegenerative loss of dopaminergic neurons to partially compensate for the deficiency and to modulate the basal ganglia circuitry.

Stalevo is a prescription medication formulated for the treatment of parkinson disease. It contains a combination of entacapone levodopa and carbidopa in a fixed ratio. Entacapone functions as a catechol-o-methyltransferase inhibitor that prolongs the activity of levodopa. Carbidopa serves to block peripheral conversion of levodopa to dopamine and thereby reduces gastrointestinal side effects. By increasing the amount of levodopa that reaches the brain, Stalevo helps restore depleted dopamine levels. The resulting rise in brain dopamine improves motor symptoms such as tremor rigidity and slowness of movement. The synergistic action of these components provides more stable symptom control and reduces the frequency of off periods. This mechanism enables patients to maintain functional mobility and quality of life throughout the progression of the disease.

Stalevo is a prescription drug formulated to treat motor symptoms associated with parkinson's disease. Like many medicines it can cause changes in blood pressure that may lead to dizziness when standing up. Some individuals experience dizziness or light-headedness, especially when rising from a sitting position. Sleepiness or fatigue may be observed, affecting daily activities in a small percentage of users. Involuntary movements known as dyskinesia can develop with prolonged use. In rare cases, visual or auditory hallucinations have been documented among patients taking the medication. Blood pressure may drop unexpectedly, leading to episodes of faintness. Mood changes such as increased anxiety or depression have also been noted in clinical reports.

Stalevo may cause nausea in some patients. It can also lead to headaches or dizziness. Some individuals experience insomnia or vivid dreams. The medication might increase blood pressure in certain cases. Liver function abnormalities have been reported rarely. Patients may also notice changes in mood or anxiety levels.